US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Poolbeg Pharma Plc

0.0661

0.0000

Volume:- -

Turnover:- -

Market Cap:46.08M

PE:-4.55

High:0.0661

Open:0.0661

Low:0.0661

Close:0.0661

52wk High:0.0661

52wk Low:0.0420

Shares:697.20M

Float Shares:529.54M

Volume Ratio:0.08

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0145

EPS(LYR):-0.0145

ROE:-46.84%

ROA:-29.22%

PB:2.86

PE(LYR):-4.56

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Poolbeg Pharma Plc

Exchange:

PINK LIMITED

Establishment Date:

2021

Employees:

16

Office Location:

40 Bank Street,Floor 24,London,Greater London,United Kingdom

Website:

http://www.poolbegpharma.com

Zip Code:

E14 5NR

Phone:

44 20 7183 1499

Fax:

- -

Introduction:

Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. In addition, it has a license to encapsulation technology for oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut. Further, the company is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/POLBF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"POLBF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"POLBF\",,,,,undefined,":{"symbol":"POLBF","market":"US","secType":"STK","nameCN":"Poolbeg Pharma Plc","latestPrice":0.0661,"timestamp":1771621200000,"preClose":0.0661,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":529535252,"shares":697200000,"eps":-0.014522,"marketStatus":"Pre-Mkt","change":0,"latestTime":"02-20 16:00:00 EST Delay","open":0.0661,"high":0.0661,"low":0.0661,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.014522,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771857000000},"marketStatusCode":1,"adr":0,"exchange":"PINK LIMITED","adjPreClose":0.0661,"volumeRatio":0.07968317955061366},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"POLBF\",,,,,undefined,":{"symbol":"POLBF","floatShares":529535252,"roa":"-29.22%","roe":"-46.84%","lyrEps":-0.014497,"volumeRatio":0.07968317955061366,"shares":697200000,"dividePrice":0,"high":0.0661,"amplitude":0,"preClose":0.0661,"low":0.0661,"week52Low":0.042,"pbRate":"2.86","week52High":0.0661,"institutionHeld":0,"latestPrice":0.0661,"eps":-0.014522,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.014522,"open":0.0661,"prevYearClose":0.0425,"prevWeekClose":0.0661,"prevMonthClose":0.0425,"prevQuarterClose":0.0425,"fiveDayClose":0.0661,"twentyDayClose":0.0425,"sixtyDayClose":0.0425},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/POLBF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-04-30","symbol":"POLBF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714449600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-09-13","symbol":"POLBF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1694577600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-03-30","symbol":"POLBF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1680148800000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"POLBF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"POLBF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1765256400000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":718912342,"yearFounded":2021,"employeeNum":16,"address":"40 Bank Street,Floor 24,London,Greater London,United Kingdom","zipCode":"E14 5NR","officePhone":"44 20 7183 1499"},"stockCompanyDetail":{"websiteUrl":"http://www.poolbegpharma.com","description":"Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. In addition, it has a license to encapsulation technology for oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut. Further, the company is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.","exchange":"PINK LIMITED","name":"Poolbeg Pharma Plc","nameEN":"Poolbeg Pharma Plc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"POLBF\",market:\"US\",,,undefined,":null}}